Form 4: 10x Genomics CEO Serge Saxonov Executes Stock Transactions Under 10b5-1 Plan

Serge Saxonov, CEO of 10x Genomics, reports stock sales and option exercises, including transactions under a previously established 10b5-1 trading plan.

Summary

• Serge Saxonov, the CEO of 10x Genomics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On February 28, 2025, Saxonov sold 7,942 shares of Class A Common Stock at a weighted average price of $10.6262 per share, with prices ranging from $10.415 to $10.78.
• These sales were executed under a Rule 10b5-1 trading plan adopted on September 12, 2024, and terminated on March 4, 2025.
• On March 4, 2025, Saxonov exercised a stock option for 50,000 shares of Class A Common Stock at an exercise price of $1.20 per share.
• Following these transactions, Saxonov directly owns 921,540 shares of Class A Common Stock.
• Saxonov also has indirect ownership through several trusts, including the Andromeda Trust (27 shares), the Sirius Trust (870 shares), the Y/S Descendants' Trust (213,250 shares), and the Y/S Pot Trust (22,570 shares).

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and there's no indication of significant concern or excitement.

Positives

• The exercise of stock options demonstrates the CEO's belief in the company's long-term value.

Negatives

• The sale of shares by the CEO, even under a pre-arranged plan, could be perceived negatively by some investors.

Risks

• Continued stock sales by insiders could create downward pressure on the stock price.
• Changes in beneficial ownership could signal shifts in management's confidence in the company's future prospects.

Industry Context

Insider transactions are common and closely watched in the biotech industry. Investors often analyze these filings for insights into management's perspective on the company's valuation and future performance. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Monitoring insider trading activity is a common practice in the biotech industry, with companies like Illumina (ILMN) and Pacific Biosciences (PACB) also subject to scrutiny of their executives' stock transactions.
• The use of 10b5-1 trading plans is a standard practice among executives in publicly traded companies to schedule stock sales in advance and avoid accusations of insider trading, similar to practices seen at companies like Regeneron (REGN) and Amgen (AMGN).

Stakeholder Impact

• Shareholders may react to the stock sales, although the pre-planned nature of the transactions should mitigate concerns.
• Employees may be interested in the CEO's stock activity as an indicator of company performance.

Key Dates